Table 2.
Subgroup analysis.
| Study characteristics | VAT (cm2) | SAT (cm2) | ||||||
|---|---|---|---|---|---|---|---|---|
| Study number | Patient number | WMD [95% Cl] | P-value | Study number | Patient number | WMD [95% Cl] | P-value | |
| Empagliflozin | 4 | 223 | -2.55 [-7.47, 2.37] | 0.31 | 1 | 51 | -1.90 [-7.49, 3.69] | 0.50 |
| Dapagliflozin | 2 | 99 | -10.01 [-27.05, 7.04] | 0.25 | 2 | 99 | -23.87 [-52.72, 4.98] | 0.10 |
| Ipragliflozin | 4 | 208 | -26.38 [-33.20, -19.57] | 0.0008 | 4 | 208 | -23.42 [-44.82, -2.03] | 0.03 |
| BMI ≥ 28(kg/m2) | 5 | 284 | -18.22 [-30.67, -5.76] | 0.004 | 3 | 161 | -16.24 [-40.27, 7.80] | 0.19 |
| BMI < 28(kg/m2) | 5 | 246 | -16.78 [-25.85, -7.71] | 0.0003 | 4 | 197 | -25.17 [-34.32, -16.02] | <0.00001 |
| Follow-up ≥ 24weeks | 7 | 368 | -17.65 [-27.40, -7.90] | 0.0004 | 6 | 296 | -19.37 [-37.08, -1.67] | 0.03 |
| Follow-up <24weeks | 3 | 162 | -11.34 [-28.70, 6.01] | 0.2 | 1 | 62 | -19.00 [-65.20, 27.20] | 0.42 |